Ethnicity-specific impact of HLA I/II genotypes on the risk of inhibitor development: data from Korean patients with severe hemophilia A

Hyun Young Kim, Jin Hee Cho, Hee Jung Kim, Hae Sun Chung, Sun Hee Kim, Ki O. Lee, Soo Young Jung, Ki Young Yoo, Hee Jin Kim

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Inhibitor development is the most serious complication in patients with hemophilia. We investigated association of HLA genotypes with inhibitor development in Korean patients with severe hemophilia A (HA). HLA genotyping was done in 100 patients with severe HA including 27 patients with inhibitors. The allele frequencies between inhibitor-positive and inhibitor-negative patients were compared. HLA class I alleles were not associated with the inhibitor status. In HLA class II, DRB1*15 [n = 100, odds ratio (OR) 0.217, P = 0.028] and DPB1*05:01 [OR 0.461, P = 0.026] were negatively associated with inhibitor development. In a subgroup of patients with intron 22 inversion, C*07:02 was positively associated with inhibitor development [n = 30, OR 5.500, P = 0.043]. In the subgroup of patients without intron 22 inversion, the negative association between DPB1*05:01 and inhibitor development was reinforced [n = 70, OR 0.327, P = 0.010], and positive association of DRB1*13:02 and DPB1*04:01 with inhibitor development was identified [OR 3.059, P = 0.037 for both]. Previously reported risk alleles were not consistently associated with inhibitor risk in our series. This study demonstrated the profile of HLA alleles associated with inhibitor risk in Korean patients with severe HA was different from that in patients of other ethnicities, which needs to be considered in risk assessment and management.

Original languageEnglish
Pages (from-to)1695-1700
Number of pages6
JournalAnnals of Hematology
Issue number9
StatePublished - 1 Sep 2018

Bibliographical note

Funding Information:
This study was approved by the Institutional Review Board of Samsung Medical Center (Seoul, Korea), and all patients gave written informed consent in accordance with the Declaration of Helsinki.

Funding Information:
Funding information This study was supported by a grant from the Korea Food & Drug Administration (KFDA) and by a grant from Korea Hemophilia Foundation.

Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature.


  • HLA genotypes
  • Hemophilia A
  • Inhibitor
  • Korea
  • Mutation


Dive into the research topics of 'Ethnicity-specific impact of HLA I/II genotypes on the risk of inhibitor development: data from Korean patients with severe hemophilia A'. Together they form a unique fingerprint.

Cite this